Scientific Sessions

Neuroimaging and biomarkers play a crucial role in modern neurology by enabling early diagnosis, accurate monitoring, and personalized treatment of neurological disorders. Neuroimaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and functional MRI (fMRI) allow clinicians and researchers to visualize the brain’s structure, function, and metabolic activity in detail. These tools are essential for identifying abnormalities such as tumors, strokes, demyelination, and neurodegenerative changes, as well as for mapping brain activity during cognitive and motor tasks. Advances in imaging technology have also made it possible to track subtle brain changes over time, supporting the early detection of conditions like Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.

Biomarkers, which include measurable biological indicators like proteins, genetic markers, or metabolites, complement neuroimaging by providing insights into disease mechanisms and progression at the molecular level. For example, cerebrospinal fluid (CSF) biomarkers such as beta-amyloid and tau proteins are critical for diagnosing Alzheimer’s disease, while neurofilament light chain (NfL) levels are emerging as markers of neuronal damage across multiple conditions. Combining imaging and biomarker data enhances diagnostic accuracy, guides therapeutic decisions, and helps evaluate the effectiveness of clinical trials for new treatments. As research advances, the integration of neuroimaging and biomarker analysis is moving toward precision medicine, offering more tailored interventions for patients. Together, these approaches are reshaping the landscape of neurological care, making it more proactive, predictive, and personalized.